Targeted Treatment of Prostate Cancer
Official Title of Study: A Single-Arm, Open-Label, Two-Stage Phase II Study of the MEK 1/2 Inhibitor Trametinib in Men with Progressive Metastatic Castrate Resistant Prostate Cancer
Disease Type: Metastatic, castration-resistant prostate cancer
Basic information: The purpose of this study is to see if the study drug, Trametinib, is safe and effective for the treatment of your prostate cancer. Trametinib is a drug that is FDA-approved for another type of cancer called metastatic melanoma. However, it is not approved for prostate cancer.
Trametinib is a drug that is taken by mouth. If you take part in this study, you will take a dose of Trametinib every day.
Research Procedures (not a complete list):
To take part in this study, you must be willing to undergo a research biopsy of your metastatic tumor before you begin treatment. Once you start treatment, you will come to the clinic every other week for the first month, then every 4 weeks thereafter, for an exam and blood tests.
Eligibility Criteria (not a complete list):
For More Detailed Information, Contact: